Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with end-stage renal disease on hemodialysis

J Ren Nutr. 2012 Mar;22(2):244-250. doi: 10.1053/j.jrn.2011.06.005. Epub 2011 Sep 10.


Objective: We examined the effects of alpha-lipoic acid (ALA) supplementation on inflammation, oxidative stress, and serum lipid profile levels in hemodialysis (HD) patients.

Design: This was a double-blinded, randomized, placebo-controlled clinical trial.

Setting: The present study involved HD centers in Tabriz, Iran.

Patients: Participants included 63 patients with end-stage renal disease (43 men and 20 women; age range: 22-79 years) undergoing maintenance HD.

Intervention: HD patients were randomly assigned into the supplemented group (n = 31), receiving a daily dose of ALA (600 mg), or a control group (n = 32), receiving placebo for 8 weeks.

Main outcome measures: High sensitivity C-reactive protein (hsCRP), malondialdehyde, total antioxidant status, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured at baseline and after 8 weeks of supplementation.

Results: At the end of intervention, 11 patients were excluded from the study. HsCRP levels decreased by 18.7% in the supplemented group after 8 weeks of supplementation, and the reduction was significant in comparison with the placebo group (P < .05); this finding was also significant after adjusting for baseline values of hsCRP. The mean malondialdehyde and total antioxidant status levels did not change significantly in the 2 groups during the study. The mean high-density lipoprotein cholesterol concentrations increased significantly in the supplemented group at the end of the study (P < .05); however, this improvement was not statistically significant as compared with the placebo group. No significant alterations were observed in the other lipid profile parameters within each group during the study.

Conclusion: ALA supplementation significantly reduced hsCRP levels, which is a risk factor for cardiovascular disease in HD patients.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antioxidants / metabolism
  • C-Reactive Protein / metabolism
  • Cholesterol / blood*
  • Dietary Supplements*
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation / blood
  • Inflammation / complications
  • Inflammation / drug therapy
  • Iran
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / drug therapy
  • Male
  • Malondialdehyde / blood
  • Middle Aged
  • Oxidative Stress / drug effects*
  • Renal Dialysis
  • Thioctic Acid / administration & dosage*
  • Triglycerides / blood*
  • Young Adult


  • Antioxidants
  • Triglycerides
  • Malondialdehyde
  • Thioctic Acid
  • C-Reactive Protein
  • Cholesterol